Literature DB >> 22050642

Aqueous humor vascular endothelial growth factor in dogs: association with intraocular disease and the development of pre-iridal fibrovascular membrane.

Christina A Sandberg1, Ian P Herring, William R Huckle, Tanya LeRoith, J Phillip Pickett, John H Rossmeisl.   

Abstract

OBJECTIVE: To examine the concentrations of vascular endothelial growth factor (VEGF) in aqueous humor of dogs with intraocular disease and to evaluate the association of aqueous humor VEGF with pre-iridal fibrovascular membrane (PIFM) formation. PROCEDURES: Two hundred and twenty six aqueous humor samples and 101 plasma samples were collected from 178 dogs with a variety of intraocular diseases (including cataract, primary glaucoma, uveitic glaucoma, aphakic/pseudophakic glaucoma, retinal detachment, lens luxation, and intraocular neoplasia), and aqueous humor was collected from 13 ophthalmically normal control dogs. Systemic disease status and administration of select medications were recorded. Aqueous and plasma VEGF was assayed via enzyme-linked immunosorbant assay validated for canine VEGF. Available histopathology samples were examined for the presence of PIFM. Where present, PIFMs were categorized as none, cellular, vascular or fibrous, and fibrovascular. Data were evaluated by mixed model anova, with application of Tukey-Kramer adjustment for multiple comparisons.
RESULTS: There was no association between aqueous humor and plasma VEGF levels. Compared with normal controls, aqueous humor VEGF was significantly elevated for all intraocular diseases (P < 0.05) except for primary and diabetic cataracts. Systemic disease and administered medications had no significant effect on aqueous humor VEGF concentration. Compared to dogs without PIFM, aqueous humor VEGF was significantly higher in dogs with fibrovascular PIFM (P = 0.001), but not cellular (P = 0.1704) or fibrous/vascular PIFM (P = 0.0667).
CONCLUSIONS: These findings confirm that VEGF is commonly elevated in aqueous humor of dogs with intraocular disease and likely plays a role in the causation or progression of a variety of intraocular disorders, including the development of PIFM.
© 2012 American College of Veterinary Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050642     DOI: 10.1111/j.1463-5224.2011.00931.x

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  4 in total

1.  Diagnostic Ophthalmology.

Authors:  Lynne S Sandmeyer; Marina Leis; Bianca Bauer
Journal:  Can Vet J       Date:  2019-05       Impact factor: 1.008

Review 2.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

Review 3.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

4.  Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series.

Authors:  Lisa-Marie Muellerleile; Michael Bernkopf; Michael Wambacher; Barbara Nell
Journal:  Vet Ophthalmol       Date:  2021-09-06       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.